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Key Points: 
Chronic asymptomatic P. falciparum infection during the dry season predicts decreased clinical 
malaria risk during the ensuing malaria season; however, treating these infections did not alter this 
reduced risk, challenging the notion that chronic P. falciparum infection maintains malaria immunity.  
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Abstract 
Background Chronic asymptomatic Plasmodium falciparum infections are common in endemic areas 
and are thought to contribute to the maintenance of malaria immunity. Whether treatment of these 
infections increases the subsequent risk of clinical episodes of malaria is unclear.  
Methods In a three-year study in Mali, asymptomatic individuals with or without P. falciparum 
infection at the end of the six-month dry season were identified by PCR, and clinical malaria risk was 
compared during the ensuing six-month malaria transmission season. At the end of the second dry 
season, three groups of asymptomatic children were identified: 1) children infected with P. falciparum 
as detected by rapid diagnostic testing (RDT) who were treated with antimalarials (n=104), 2) RDT-
negative children whose untreated P. falciparum infections were detected retrospectively by PCR 
(n=55), and 3) uninfected children (RDT/PCR negative) (n=434). Clinical malaria risk during two 
subsequent malaria seasons was compared. P. falciparum-specific antibody kinetics during the dry 
season were compared in children who did or did not harbour asymptomatic P. falciparum infections.  
Results Chronic asymptomatic P. falciparum infection predicted decreased clinical malaria risk 
during the subsequent malaria season(s); treatment of these infections did not alter this reduced risk. P. 
falciparum-specific antibodies declined similarly in children who did or did not harbour chronic 
asymptomatic P. falciparum infection during the dry season.  
Conclusions These findings challenge the notion that chronic asymptomatic P. falciparum infection 
maintains malaria immunity and suggest that mass drug administration during the dry season should 
not increase the subsequent risk of clinical malaria.   
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Introduction 
 
Plasmodium falciparum is responsible for ~200 million cases of malaria and 400,000 deaths annually 
[1]. Encouragingly, the scale up of mosquito control measures and artemisinin-based combination 
therapy has been associated with reduced malaria burden in many regions [2]. Consequently, an 
increasing number of endemic countries are working towards elimination and considering the 
interventions that will be required to achieve this objective. Importantly, a large proportion of people 
in endemic areas are infected with P. falciparum without symptoms [3, 4]. This clinically silent 
parasite reservoir, which persists for months to years [5] and contributes to ongoing malaria 
transmission [4, 6-9], poses a challenge for elimination efforts. The strategies of antimalarial mass 
drug administration (MDA) to at risk populations or mass screening and treatment (MSAT) of 
asymptomatically infected individuals are being considered in certain settings [10-12], particularly in 
areas of seasonal transmission where MDA during the dry season could reduce the number of 
gametocyte carriers and decrease transmission to the mosquito vector as the rainy season ensues [11, 
13, 14]. 
 
However, asymptomatic P. falciparum infections have long been thought to directly contribute to the 
maintenance of immunity to malaria, a notion referred to as ‘premunition’ [15-17]. Consistent with 
this hypothesis, studies in areas of seasonal malaria have shown that asymptomatic P. falciparum 
infection at the end of the dry season predicts decreased risk of febrile malaria during the ensuing 
malaria season [18-22]. This raises the question of whether treatment of asymptomatic infections 
during the dry season might increase the risk of symptomatic malaria in the event of P. falciparum re-
infection. 
 
Two studies in areas of seasonal malaria assessed the impact of treating asymptomatic P. falciparum 
infection during the dry season on the subsequent risk of clinical malaria. A trial in the Gambia 
randomized villages to placebo versus one dose of sulfadoxine-pyrimethamine combined with one 
dose of artesunate and found no difference in malaria incidence during 20 weeks of follow-up, 
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although there was a significant drop in the incidence of malaria during the period immediately after 
drug administration [23]. Similarly, a trial in Burkina Faso randomized villages to screening and 
treatment of asymptomatic P. falciparum infection with artemether-lumefantrine (AL) or no 
intervention and found no difference in the subsequent incidence of malaria [24]. In contrast, a study 
in the Zambia—where malaria transmission is year-round—randomized health districts during the low 
transmission season to screening and treatment of infected individuals with AL or no intervention and 
found a modest decrease in malaria risk in the intervention group [25].  
 
Importantly, these studies compared malaria risk at the community rather than individual level, which 
may have confounded the results due to heterogeneity in P. falciparum transmission across 
communities. Additionally, at the time of treatment these studies did not distinguish chronic 
asymptomatic P. falciparum infection from recently transmitted infections that may have progressed 
to clinical malaria without treatment [26], and which may have different effects on host immunity. 
Together, the limitations of these studies leave open the question of whether treatment of chronic 
asymptomatic P. falciparum infection impacts the subsequent risk of clinical malaria at the individual 
level. 
 
In this longitudinal study conducted in an area of seasonal malaria we addressed four objectives: 1) 
determine whether asymptomatic P. falciparum parasitemia detected at the end of the six-month dry 
season represents chronic infection, 2) confirm that asymptomatic P. falciparum infections during the 
dry season predict protection from clinical malaria during the ensuing malaria season, 3) determine the 
impact of treating asymptomatic P. falciparum infection during the dry season on the subsequent risk 
of clinical malaria, and 4) determine whether chronic asymptomatic P. falciparum infection maintains 
P. falciparum-specific humoral immunity. 
 
METHODS 
 
Ethics statement  
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The Ethics Committee of the FMPOS at the University of Bamako, and the NIAID/NIH IRB approved 
this study. Written informed consent was obtained from all subjects and the parents/guardians of 
participating children. The study is registered on http://www.clinicaltrials.gov (NCT01322581). 
 
Study design and participants  
From May 2011 through December 2013 a cohort study was conducted in Kalifabougou, Mali, a rural 
village of ~5000 inhabitants where malaria transmission occurs from July through December. A single 
clinic and pharmacy provided the only access to antimalarial drugs. A detailed description of the study 
site and cohort design has been published elsewhere [27]. From an age-stratified, random sample of 
the entire village population, 695 healthy individuals aged six months to 25 years were enrolled. 
Exclusion criteria were haemoglobin concentration <7 g/dL, axillary temperature ≥37.5°C, acute 
systemic illness, or use of antimalarial or immunosuppressive medications in the preceding 30 days. 
Clinical malaria episodes were detected prospectively by active and passive surveillance and were 
defined by an axillary temperature of ≥37.5°C, ≥2500 asexual parasites/μL of blood, and no other 
cause of fever on physical examination.  
 
Detection of P. falciparum infection 
Thick blood smears were stained with Giemsa and Plasmodium parasites were counted against 300 
leukocytes; parasite densities were recorded as the number of parasites/µL of whole blood based on a 
mean leukocyte count of 7500 cells/µL. Two expert microscopists evaluated each smear separately, 
and a third resolved discrepancies. The First Response® Combo Malaria Ag (pLDH/HRP2) card was 
used as a rapid diagnostic test (RDT), the sensitivity of which is ~100 parasites/μl [28]. Nested PCR 
amplification of Plasmodium DNA was performed from dried blood spots as previously described 
[27], the sensitivity of which is ~0.5 - 1 parasites/μl [27].  
 
Additional methods are described online in supplementary information. 
 
Results 
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Asymptomatic P. falciparum infection during the dry season is associated with lower risk of 
clinical malaria during the ensuing malaria season 
 
We sought to confirm prior studies that associated asymptomatic P. falciparum infection with lower 
risk of clinical malaria [18, 19, 21, 22]. During a two-week period in May 2011 we enrolled 695 
asymptomatic subjects just prior to the 6-month malaria season (Figure 1A). The prevalence of P. 
falciparum infection at enrolment was 45.6% by PCR and 26.3% by blood smear. The prevalence of 
infection by PCR plateaued by 8 years of age, while the prevalence by blood smear declined after 8 
years of age (Figure 1B), consistent with an age-dependent decrease in parasitemia [27].  
 
During the ensuing six-month malaria season, clinical malaria episodes were detected by weekly 
active surveillance and self-referral. Consistent with prior studies [18-22], asymptomatic P. 
falciparum infection at the end of the dry season was associated with lower risk of febrile malaria 
during the ensuing malaria season (p<0.0001; Figure 1C), an association that remained significant 
after adjusting for age, gender and hemoglobin (Hb) type (P<0.0001; Figure 1D). The risk of febrile 
malaria was not significantly different between PCR+smear+ subjects and PCR+smear– subjects 
(p=0.51; Figure 1C), indicating that the difference in baseline parasitemia between these groups did 
not affect subsequent malaria risk. Hereafter, all analyses focus on children ≤11 years of age—the age 
group that experiences the majority of clinical malaria episodes in this cohort [27]. 
 
Treatment of chronic asymptomatic P. falciparum infection does not change the risk of clinical 
malaria during the subsequent malaria season 
 
The association between asymptomatic P. falciparum infection during the dry season and subsequent 
protection from febrile malaria suggests that treatment of asymptomatic infection at the end of the dry 
season could increase the risk of clinical malaria during the ensuing malaria season. To test this 
hypothesis, we screened the same cohort for P. falciparum infection (all asymptomatic) at the end of 
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the second dry season (May 2012) using an RDT with a sensitivity comparable to blood smear [29]. 
All subjects found to be P. falciparum-infected by RDT (n=104) were treated with a standard 3-day 
course of AL, the first daily dose of which was directly observed by study staff. Dried blood spots 
collected from RDT– subjects at the same timepoint (n=489) were later analyzed by PCR to 
retrospectively identify two additional groups that did not receive antimalarials: RDT–PCR+ subjects 
(n=55) and RDT–PCR– subjects (n=434).  
 
Because asymptomatic P. falciparum infections detected during cross-sectional surveys can become 
symptomatic within days or weeks of initial detection [3, 4, 30], we sought to confirm that P. 
falciparum infections detected at the end of the dry season in May 2012 were chronic and 
asymptomatic. We found that subjects infected with P. falciparum in May 2012 were highly likely to 
have been infected at the start of the dry season (January 2012) [OR: 842.6 c.i. (200.2, 3546.3), P < 
0.0001]; and through the mid-dry season (March 2012) [OR: 172.9 c.i. (79.8, 374.5), P < 0.0001]; and 
conversely, uninfected subjects at the start of the dry season remained uninfected at the end of the dry 
season (Supplementary Figure 1). During the same time period, no cases of clinical malaria were 
detected. We also examined parasites collected in January and May 2012, from individuals who tested 
PCR+ in May 2012, for 6 microsatellite loci previously used to characterize the genetic diversity of P. 
falciparum [31], and we obtained low Fst values between the populations (Fst January vs. May = 0.004), 
indicating that the two populations were genetically very similar (Figure 2A). Additionally, analysis of 
the polymorphic region of the P. falciparum msp2 locus in January and May 2012 indicated that 
asymptomatic infections were polyclonal at both timepoints and 47% of subjects harboured at least 
one common parasite clone at both timepoints (Figure 2B). Together with our observation that the 
entomological inoculation rate is near zero during the dry season, these data indicate that 
asymptomatic P. falciparum infections detected at the end of the dry season had persisted as chronic 
asymptomatic infections throughout the preceding dry season. 
 
The characteristics of the three groups defined in May 2012 (RDT+ treated, RDT–PCR+ untreated, and 
RDT–PCR– untreated) are shown in Table 1. Consistent with the first year of the study, the RDT–PCR– 
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group had the highest risk of febrile malaria during the second malaria season (Figure 3A), while 
febrile malaria risk in the RDT+ treated and RDT–PCR+ untreated groups was similar in both 
univariate (Figure 3A) and multivariate analyses (Figure 3B). We observed the same pattern during 
the third malaria season (Figure 3C and 3D), indicating that treatment of chronic asymptomatic P. 
falciparum infection at the end of the dry season does not change the risk of clinical malaria during 
two subsequent malaria seasons.  
 
P. falciparum-specific humoral immunity decreases similarly with or without chronic 
asymptomatic infection 
 
Because treatment of asymptomatic P. falciparum infection at the end of the dry season did not 
increase the subsequent risk of febrile malaria, we hypothesized that chronic asymptomatic P. 
falciparum infection per se does not maintain malaria immunity, but is instead a marker of higher past 
P. falciparum exposure and thus higher cumulative immunity. We tested this hypothesis by comparing 
antibody responses to 862 P. falciparum proteins before and after the dry season in age-matched 
children who did or did not harbour asymptomatic P. falciparum over the same time period. At both 
timepoints the breadth and magnitude of P. falciparum-specific antibodies were higher in subjects 
who carried parasites through the dry season (Figure 4A-C); however, both antibody breadth and 
magnitude decreased similarly during the dry season in infected and uninfected subjects (Figures 4D 
and 4E), suggesting that chronic asymptomatic P. falciparum infection per se does not contribute 
significantly to the maintenance of humoral immunity to malaria.  
 
Discussion 
 
Here we investigated the impact of treating chronic asymptomatic P. falciparum at the end of the dry 
season on the subsequent risk of clinical malaria. In doing so we tested the long-standing hypothesis 
that asymptomatic P. falciparum infection maintains immunity to malaria [15-17, 32, 33]. We found 
that treatment of asymptomatic P. falciparum infection at the end of the dry season did not increase 
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clinical malaria risk at the individual level during two subsequent malaria seasons. Moreover, P. 
falciparum-specific antibodies declined at a similar rate in children who did or did not harbour 
asymptomatic P. falciparum over the dry season. Together these findings challenge the notion that 
asymptomatic P. falciparum infection maintains clinical and humoral immunity to malaria and suggest 
that MDA during the dry season should not increase the subsequent risk of clinical malaria at the 
individual level. In contrast, seasonal malaria chemoprevention (SMC) [34] - which prevents the 
progression of new blood-stage infections during the transmission season - has been associated in 
some studies with increased malaria risk (i.e. rebound) after discontinuation of SMC [35, 36]. 
Therefore, we hypothesize that recently transmitted P. falciparum parasites more effectively induce 
immune responses relative to parasites that have persisted in blood for several months during the dry 
season. A differential capacity to trigger host immune responses could reflect epigenetic, 
transcriptional and metabolic differences between newly transmitted parasites and parasites that persist 
during long periods of asexual replication in blood.  
 
We found that the breadth and magnitude of IgG specific for 862 P. falciparum proteins/polypeptides 
declined at a similar rate in children who did or did not carry asymptomatic P. falciparum infection 
during the dry season. Similarly,Consistent with our antibody data, a study comparing Gambian 
children who did or did not carry P. falciparum parasites during the dry season found no difference in 
the rate of decline of IgG specific for three P. falciparum merozoite antigens (AMA1, EBA175, 
MSP119), whereas IgG specific for the merozoite antigen MSP2 declined more rapidly in uninfected 
children [37], suggesting interactions between specific antigens and infection status that require 
further investigation. We cannot exclude a role for chronic P. falciparum infection in maintaining 
other facets of host immunity such as cell-mediated immunity or regulatory mechanisms that attenuate 
malaria-induced inflammation. Our prior work in Mali suggests that asymptomatic infection during 
the dry season maintains P. falciparum-inducible IL-10 production capacity in some individuals; 
however, the magnitude of this response is much lower than that observed in the same children during 
the preceding transmission season one week after acute febrile malaria [38]. This is consistent with 
other studies in this population that showed a marked increase in P. falciparum-specific memory B 
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cells and antibodies during acute malaria that waned rapidly during the subsequent dry season [39, 
40]. Together these observations suggest that the maintenance of malaria immunity depends on 
repeated exposures to newly transmitted parasites.  
 
Of note, we observed no difference in baseline Hb levels among uninfected subjects and 
asymptomatically infected subjects, possibly explained in part by the exclusion of subjects with Hb <7 
g/dL from this study. Moreover, treatment of asymptomatic P. falciparum infection did not change the 
prevalence of anemia one year later (Supplementary Figure 2), which is consistent with a study in 
Kenya [41], but at odds with other studies [24, 42].  
 
This study has limitations. First, subjects were not blinded to treatment status, which could have led to 
differences in treatment seeking behavior. However, this was likely mitigated by weekly active 
surveillance for symptomatic malaria. Second, subjects were not randomized to treatment or no 
treatment groups, but were classified as such based on the RDT result at the end of the dry season, 
which may have led to differences between groups in known and unknown factors that affect malaria 
risk. The most important factors known to influence malaria risk in this cohort are age and Hb type 
[43], which did not differ significantly between the RDT+ treated and RDT–PCR+ untreated groups. 
Moreover, subjects who were blood smear+ or blood smear–PCR+ at the end of the first dry season had 
the same risk of clinical malaria during the first year of the study. Although we did not control for 
socioeconomic factors, the study population was an age-stratified random sample of individuals 
residing in a rural community where socioeconomic conditions are relatively uniform and where the 
research clinic was the only local source of antimalarials. Moreover, it seems unlikely that 
socioeconomic factors confounded the results such that children who were infected with P. falciparum 
before the malaria season were more likely to experience malaria during the transmission season, since 
we observed the opposite effect in this study. Thirdly, a larger study may have detected smaller 
differences in the risk of clinical malaria between groups. Finally, the average age of the RDT+ treated 
and RDT–PCR+ untreated groups was ~8 years, so further studies are needed to determine the impact 
of treating chronic asymptomatic P. falciparum infection in younger children. 
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Recent studies in endemic areas have shown that more sensitive detection methods reveal larger 
reservoirs of asymptomatic P. falciparum infection than previously appreciated [44, 45]. Therefore, it 
is possible that some subjects in this study had parasite densities below the detection limit of our PCR 
assay. However, the primary objective of this study was to compare febrile malaria risk in RDT+ 
treated subjects vs. RDT-PCR+ untreated subjects, so the possibility that some PCR- subjects were 
infected is unrelated to the major conclusions of this study. Moreover, if a significant proportion of 
PCR- subjects were actually infected, it would be difficult to reconcile their superior ability to 
suppress parasitemia during the dry season with their lower breadth and magnitude of P. falciparum-
specific antibodies and higher risk of febrile malaria during the ensuing malaria season.  
 
Because this study does not support a causal link between chronic asymptomatic P. falciparum 
infection and protection from febrile malaria, the question remains: what underlies the association 
between asymptomatic infection and decreased malaria risk? Longitudinal analysis of P. falciparum-
specific IgG responses in this study suggest that asymptomatic infection during the dry season is 
simply a marker of higher past P. falciparum exposure and thus higher cumulative humoral immunity 
to malaria. It is also possible that the protective immunomodulatory effects of asymptomatic infection 
persist beyond antimalarial treatment at the end of the dry season into the subsequent transmission 
season—a possibility that could be tested by treating asymptomatic infections at the beginning of the 
dry season and ensuring that clearance is sustained by repeated screening and MDA.  
 
In summary, treatment of chronic asymptomatic P. falciparum infection at the end of the dry season 
did not change the subsequent risk of clinical malaria, and P. falciparum-specific antibodies declined 
similarly in children who did or did not harbour chronic asymptomatic P. falciparum infection during 
the dry season. These findings challenge the notion that chronic asymptomatic P. falciparum infection 
maintains malaria immunity and suggest that MDA during the dry season may not increase the 
subsequent risk of clinical malaria at the individual level. 
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Table 1. Characteristics of study participants stratified by infection status at the end of 
the second dry season. 
 
  
 20 
Figure Legends 
Figure 1. Asymptomatic P. falciparum infection at the end of the dry season 
independently predicts decreased febrile malaria risk during the ensuing malaria 
season. (A) Frequency of clinical malaria episodes every 2 days over three years in a cohort 
of 695 subjects aged 3 mos - 25 yrs. Clinical malaria defined as axillary temperature ≥37.5°C, 
≥2500 asexual parasites/μL of blood and no other cause of fever discernible on physical 
exam. (B) Age-stratified point prevalence of asymptomatic P. falciparum infection detected 
by PCR or blood smear at the end of the dry season in May 2011. (C) Kaplan-Meier analysis 
of time to first febrile malaria episode during the 2011 malaria season stratified by P. 
falciparum infection status in May 2011. Pairwise comparisons by log rank test: PCR+smear+ 
vs. PCR–smear–(p<0.0001); PCR+smear– vs. PCR–smear- (p<0.0001); PCR+smear+ vs. 
PCR+smear– (p=0.51). (D) Cox model showing the effect of P. falciparum infection status in 
May 2011 on the risk of febrile malaria during the ensuing 2011 malaria season, adjusted for 
covariates. Hazard ratios and 95% confidence intervals are represented by open circles and 
horizontal bars, respectively.  
 
Figure 2. Genetic evidence that P. falciparum infections persist throughout the six-
month dry season. (A) Six P. falciparum microsatellite loci were examined in peripheral 
blood samples collected from 91 P. falciparum-infected subjects in January and May 2012. 
Each color represents different allele sizes after adjustment to 3 bp bins. (B) Proportion of 
subjects with different number of P. falciparum clones determined by size differences in the 
polymorphic region of msp2 in January (n=124) and May 2012 (n=128) and overlapping at 
the two cross-sectional timepoints (n=90) in the respective age groups. 
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Figure 3. Treatment of chronic asymptomatic P. falciparum infection does not change 
the subsequent risk of febrile malaria. (A) Kaplan-Meier analysis of time to first febrile 
malaria episode during the 2012 malaria season stratified by P. falciparum infection and 
treatment status at the end of the dry season in May 2012. Pairwise comparisons by log rank 
test: RDT+/treated vs. PCR– (p<0.0001); RDT–PCR+/untreated vs. PCR– (p<0.0001); 
RDT+/treated vs. RDT–PCR+/untreated (p=0.26). (B) Cox model showing the effect of P. 
falciparum infection and treatment status in May 2012 on the risk of febrile malaria during 
the ensuing 2012 malaria season, adjusted for covariates. (C) Kaplan-Meier analysis of time 
to first febrile malaria episode during the 2013 malaria season stratified by P. falciparum 
infection and treatment status at the end of the dry season in May 2012. Pairwise comparisons 
by log rank test: RDT+/treated vs. PCR– (p<0.0001); RDT–PCR+/untreated vs. PCR– 
(p<0.0001); RDT+/treated vs. RDT–PCR+/untreated (p=0.066). (D) Cox model showing the 
effect of P. falciparum infection and treatment status in May 2012 on the risk of febrile 
malaria during the 2013 malaria season, adjusted for covariates. Hazard ratios and 95% 
confidence intervals are represented by open circles and horizontal bars, respectively. 
 
Figure 4. P. falciparum-specific IgG reactivity decreases during the dry season 
irrespective of P. falciparum infection status. (A) Breadth of IgG response in January and 
May 2012 stratified by P. falciparum infection status in May 2012. (B) Magnitude of IgG 
reactivity in January and May 2012 stratified by P. falciparum infection status in May 2012. 
(C) Magnitude of IgG response in January and May 2012 for antigens that were reactive at 
both timepoints (2 SDs above the no DNA control), stratified by P. falciparum infection 
status in May 2012. (D) Proportion of antigens to which the level of IgG reactivity fell below 
the level of detection between January and May 2012 stratified by P. falciparum infection 
status in May 2012. (E) Change in magnitude of IgG reactivity for antigens that were reactive 
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in January and May 2012, stratified by P. falciparum infection status in May 2012. Breadth is 
defined as the number of antigens to which the level of IgG reactivity exceeds 2 SDs above 
the no DNA control. Magnitude is defined as the sum of log2-IgG intensity values for all 
antigens per sample. Boxes indicate median, 25th and 75th percentiles. Values greater than 1.5 
times the IQR are plotted as individual points (Tukey’s method). 
 
